Phase 4
Completed N=10
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
Vulvovaginal Atrophy · Dyspareunia
Source: ClinicalTrials.gov NCT02784613 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcomePrimary: Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography — 8 points improvement on VGTA scale — p=0.05
◆ Published Evidence
Established
33citations · ~4 / year
Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study.
Summary
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene daily for twenty weeks. After the informed consent is signed, a baseline physical examination, and vulvoscopy with detailed photography of the vulva, vestibule and vagina, will be performed. Physical examination and vulvoscopy with detailed photography of the vulva, vestibule and vagina, will be repeated prospectively every 4 weeks for a total of 20 weeks. Therefore, physical examination and vulvoscopy with detailed photography of the vulva, vestibule and vagina will be performed prospectively at baseline (vulvoscopy session 1), 4 weeks (vulvoscopy session 2), 8 weeks (vulvoscopy session 3), 12, weeks (vulvoscopy session 4), 16 weeks (vulvoscopy session 5) and 20 weeks (vulvoscopy session 6) following daily administration of 60 mg ospemifene.
Linked Publications
-
Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visible Changes to the Vulva, Vestibule and Vaginal Region on Photography |
8 | 0.05 |
| SECONDARY Changes in Pain Scale |
10 | — |
| SECONDARY Percentage of Sexual Encounters in Which Pain Was Experienced |
80; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Subject provides written informed consent and HIPAA authorization before any study procedures are conducted
- Subject is female
- Subject is aged 21-80 years
- Subject has a body mass index (BMI) 40 milli-International unit /mL
- Subject has vulvovaginal atrophy with dyspareunia
- Subject has had a normal mammogram within the last 6 months
- Subject has normal pap smear within last 6 months
- Subject has an endometrial stripe ≤ 4 mm within the last 6 months if she has a uterus
- Subject agrees to comply with the study procedures and visits.
Exclusion Criteria
- Subject has a hypersensitivity to any of the ingredients of ospemifene
- Subject has used ospemifene in the past
- Subject has documented or suspected breast cancer, history of heart attack or stroke
- Subject has clinically significant findings on physical examination
- Subject has uncontrolled hypertension
- Subject has any chronic medical condition or psychologic disorder that the Principal Investigator feels makes her ineligible for the study
- Subject is currently on local or systemic androgen therapy including local or systemic testosterone (washout 14 days for local or topical androgen or non-depot injection, 1 month for depot, 6 months for pellet
- Subject is currently on local or systemic estrogen therapy or androgen therapy (washout 14 days for vaginal estrogen, 60 days for oral/transdermal therapy)
- Subject is currently using a Selective Estrogen Receptor Modulator (SERM) or products that have estrogenic or anti-estrogenic effects within last month
- Subject currently using itraconazole, ketoconazole, digitalis or alkaloids heparin or strong cytochrome P 450 3A4 inhibitors
- Subject has a history of substance abuse within 12 months prior, or consuming > 14 alcoholic drinks per week
- Subject has received an investigational drug within 30 days prior to signing consent
- Subject has any condition or exhibits behavior that indicates to the Principal Investigator that the Subject is unlikely to be compliant with study procedures and visits.
Data sourced from ClinicalTrials.gov (NCT02784613) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.